UVA Health study evaluates real-world outcomes of histotripsy for liver cancer

Researchers at UVA Health have evaluated the real-world effectiveness and safety of histotripsy, a noninvasive procedure used to treat liver tumors. The study, led by surgical oncologist Allan Tsung, MD, analyzed outcomes from 972 patients who underwent the procedure between 2023 and 2026.

The findings indicated that the treatment is associated with low rates of procedural complications and laboratory toxicity. However, the study noted that 11% of patients died within 30 days of the procedure. Dr. Tsung noted that while the procedure itself was well-tolerated, the mortality rate suggests that advanced cancer and overall disease burden may have influenced these outcomes rather than the treatment itself.

The results highlight a need to better identify which specific patient populations are most likely to benefit from histotripsy, particularly regarding those with advanced disease and limited life expectancy.